Correction: Nods for Atezolizumab and Nivolumab From FDA

Cancer Discovery - United States
doi 10.1158/2159-8290.cd-17-0566
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors

Unknown

Publisher

American Association for Cancer Research (AACR)

Related search

Correction To: FDA and EMA Biosimilar Approvals

Journal of General Internal Medicine
Internal Medicine
2019English

Looking for the Best Immune-Checkpoint Inhibitor in Pre-Treated NSCLC Patients: An Indirect Comparison Between Nivolumab, Pembrolizumab and Atezolizumab

International Journal of Cancer
Cancer ResearchOncology
2017English

Sequential Atezolizumab Achieved Remarkable Efficacy After Local Radiotherapy in a Patient With Lung Adenocarcinoma Refractory to Nivolumab

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2019English

From the FDA: Test for Alcohol Screening

Journal of the American Osteopathic Association, The
MedicineAlternative MedicineComplementary
1993English

From the FDA: FDA Warns About Sleep Aids

Journal of the American Osteopathic Association, The
MedicineAlternative MedicineComplementary
1999English

First-Line Atezolizumab OK'd for SCLC

Cancer Discovery
Oncology
2019English

Correction To: Pericardial Effusion Under Nivolumab: Case-Reports and Review of the Literature

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2019English

From the FDA: Expanded Use Granted for Implantable Defibrillators

Journal of the American Osteopathic Association, The
MedicineAlternative MedicineComplementary
1996English

From the FDA: Home Screening Test for HIV Approved

Journal of the American Osteopathic Association, The
MedicineAlternative MedicineComplementary
1996English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy